Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/PER-028-04
PER-028-04Completed未知

MULTICENTER STUDY RANDOMIZED, DOUBLE-BLIND, CONTROLLED WITH PLACEBO, OF PARALLEL GROUPS, WITH MULTIPLE DOSE (7DAYS) AND DOSE RANGE TO EVALUATE THE EFFICACY AND SAFETY OF 4 DOSES OF QAB149 (50, 100, 200 AND 400 UG) ADMINISTERED THROUGH INHALER OF DRY POWDER MULTIDOSIS AND 1 DOSAGE OF QAB149 (400UG) ADMINISTERED THROUGH DRY POWDER INHALER MONODOSIS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

OVARTIS BIOSCIENSES PERU S.A.,0 sites0 target enrollmentStarted: July 8, 2004Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
0 to 0 (—)

Inclusion Criteria

  • •Diagnosis of COPD
  • •Age 40-75 years
  • •Smoking history

Exclusion Criteria

  • •Other serious disease
  • •Allergy to QAB149
  • •Respiratory tract infection

Investigators

Sponsor
OVARTIS BIOSCIENSES PERU S.A.,

Similar Trials

Completed
Not Applicable
Study In People With Type 2 Diabetes
PER-061-05GLAXOSMITHKLINE PERU S.A.,
Completed
Not Applicable
TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES WITH AN INVESTIGATIONAL NEW DRUG
PER-084-02GLAXOSMITHKLINE RESEARCH TRIANGLE PARK,
Completed
Not Applicable
8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertensio
PER-068-06OVARTIS BIOSCIENSES PERU S.A.,
Active, not recruiting
Not Applicable
RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF THE EFFICACY, TOLERABILITY AND SAFETY OF VALDECOXIB (BEXTRA®)10 MG OD VS. DICLOFENAC SODIUM 50 MG TDS FOR 6 WEEKS IN SUBJECTS WITH OSTEOARTHRITIS OF THE KNEE. - N/AOsteoarthritis of the kneeClassification code 10031161
EUCTR2004-001713-34-GBPfizer Limited516
Completed
Not Applicable
MULTICENTRIC, RANDOMIZED, DOUBLE-BLIND STUDY, IN PARALLEL GROUPS, WITH ACTIVE CONTROL, OF 24 WEEKS OF DURATION, TO EVALUATE THE EFFICACY OF THE COMBINATION VALSARTAN / HYDROCHLOROTHYAZIDE VERSUS AMLODIPINE ON THE SYSTOLIC ARTERIAL PRESSURE IN PATIENTS WITH MODERATE HYPERTENSION WITH RISK FACTORS AND / OR CARDIOVASCULAR CONCOMYANT DISEASE-I10 Essential (primary) hypertensionEssential (primary) hypertensionI10
PER-010-03OVARTIS BIOSCIENSES PERU S.A.,